INIT Stock Overview
A clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Initiator Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 8.15 |
| 52 Week High | SEK 12.20 |
| 52 Week Low | SEK 6.72 |
| Beta | 0.76 |
| 11 Month Change | -13.76% |
| 3 Month Change | -11.99% |
| 1 Year Change | 7.24% |
| 33 Year Change | 13.19% |
| 5 Year Change | n/a |
| Change since IPO | 40.52% |
Recent News & Updates
We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn
May 31
Health Check: How Prudently Does Initiator Pharma (STO:INIT) Use Debt?
Feb 27Recent updates
We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn
May 31Health Check: How Prudently Does Initiator Pharma (STO:INIT) Use Debt?
Feb 27Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?
May 20Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?
Jan 06We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn
Oct 26We're Not Very Worried About Initiator Pharma's (NGM:INIT) Cash Burn Rate
Jun 12Shareholder Returns
| INIT | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -6.3% | -5.9% | -6.7% |
| 1Y | 7.2% | 13.3% | 9.9% |
Return vs Industry: INIT underperformed the Swedish Biotechs industry which returned 13.3% over the past year.
Return vs Market: INIT underperformed the Swedish Market which returned 9.9% over the past year.
Price Volatility
| INIT volatility | |
|---|---|
| INIT Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: INIT's share price has been volatile over the past 3 months.
Volatility Over Time: INIT's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 3 | Claus Olesen | www.initiatorpharma.com |
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes IPED2015, a drug candidate which is in clinical phase 2a for the treatment of organic erectile dysfunction; IP2018, a monoamine reuptake inhibitor completed Phase IIa for the treatment of psychogenic erectile dysfunction primarily targeting the serotonin followed by the dopamine system; and IPTN2021, a Phase 1 clinical drug program targeting an orphan drug indication in severe neuropathic pain, and trigeminal neuralgia. The company also developing IP2017, a proprietary triple reuptake inhibitor; and IP2016, a preclinical development for the treatment of depression.
Initiator Pharma A/S Fundamentals Summary
| INIT fundamental statistics | |
|---|---|
| Market cap | SEK 431.25m |
| Earnings (TTM) | -SEK 27.36m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-15.8x
P/E RatioIs INIT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INIT income statement (TTM) | |
|---|---|
| Revenue | DKK 0 |
| Cost of Revenue | DKK 18.28m |
| Gross Profit | -DKK 18.28m |
| Other Expenses | -DKK 552.00k |
| Earnings | -DKK 17.73m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 23, 2024
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did INIT perform over the long term?
See historical performance and comparison